United States Thyroid Cancer Drugs Market Research Report 2022: Cabozantinib-S-Malate, Caprelsa, Cometriq, Doxorubicin Hydrochloride, Ipilimumab, Lenvatinib Mesylate, Nivolumab, and Vandetanib – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Thyroid Cancer Drugs Market Research Report by Drug Type (Cabozantinib-S-Malate, Caprelsa, and Cometriq), End User, State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.

The United States Thyroid Cancer Drugs Market size was estimated at USD 120.32 million in 2021, USD 129.51 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.52% to reach USD 207.72 million by 2027.

In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward.

The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects.

It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Thyroid Cancer Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space.

It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate.

The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

• Abbott Laboratories
• Alara Pharmaceutical Corporation
• App pharmaceuticals LLC
• AstraZeneca PLC
• Baxter International Inc.
• Bayer AG
• Bio-Path Holdings
• Biovista Inc.
• Bristol Myers co.
• Cytori Therapeutics, Inc.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Exelixis Inc.
• GlaxoSmithKline PLC
• Jerome Stevens Pharmaceuticals Inc.
• Lupin
• Merck & Co., Inc
• Mylan Pharmaceuticals Inc.
• Novartis International AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd
• Vascular Biogenics Ltd.

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Segmentation & Coverage

1.3. Years Considered for the Study

1.4. Currency & Pricing

1.5. Language

1.6. Limitations

1.7. Assumptions

1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective

2.2. Determine: Research Design

2.3. Prepare: Research Instrument

2.4. Collect: Data Source

2.5. Analyze: Data Interpretation

2.6. Formulate: Data Verification

2.7. Publish: Research Report

2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics

5.1.1. Drivers

5.1.2. Restraints

5.1.3. Opportunities

5.1.4. Challenges

5.2. Cumulative Impact of COVID-19

6. Thyroid Cancer Drugs Market, by Drug Type

6.1. Introduction

6.2. Cabozantinib-S-Malate

6.3. Caprelsa

6.4. Cometriq

6.5. Doxorubicin Hydrochloride

6.6. Ipilimumab

6.7. Lenvatinib Mesylate

6.8. Nivolumab

6.9. Vandetanib

7. Thyroid Cancer Drugs Market, by End User

7.1. Introduction

7.2. Hospitals

7.3. Oncology Clinics

7.4. Research Organizations

8. California Thyroid Cancer Drugs Market

9. Florida Thyroid Cancer Drugs Market

10. Illinois Thyroid Cancer Drugs Market

11. New York Thyroid Cancer Drugs Market

12. Ohio Thyroid Cancer Drugs Market

13. Pennsylvania Thyroid Cancer Drugs Market

14. Texas Thyroid Cancer Drugs Market

15. Competitive Landscape

15.1. FPNV Positioning Matrix

15.1.1. Quadrants

15.1.2. Business Strategy

15.1.3. Product Satisfaction

15.2. Market Ranking Analysis

15.3. Market Share Analysis, By Key Player

15.4. Competitive Scenario

15.4.1. Merger & Acquisition

15.4.2. Agreement, Collaboration, & Partnership

15.4.3. New Product Launch & Enhancement

15.4.4. Investment & Funding

15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles

For more information about this report visit https://www.researchandmarkets.com/r/d5e4kk

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900